On March 6, it was reported that the innovative drug sector performed strongly during early trading. As of press time,$3SBIO (01530.HK)$Up nearly 9%,$HUTCHMED (00013.HK)$rose more than 8%,$INNOVENT BIO (01801.HK)$up nearly 6%,$HENGRUI PHARMA (01276.HK)$Surging over 5%,$KEYMED BIO-B (02162.HK)$rose by 5%.
In terms of news, the biopharmaceutical industry was explicitly included as a 'new pillar industry' at the national level in this year's government work report during the National People’s Congress meetings, alongside industries such as integrated circuits, aerospace, and low-altitude economy. This marks the first time the government work report has positioned the development of the biopharmaceutical industry as a pillar industry, signaling an important policy direction aimed at accelerating industrial upgrading.
Southwest Securities noted that announcements of collaboration and licensing deals by multiple companies validate their research and development capabilities. The total business development (BD) package for the first two months of 2026 exceeded USD 50 billion, nearing 40% of the total for 2025, with upfront payments surpassing USD 3 billion, exceeding 40% of the amount in 2025. The fundamentals of the innovative drug sector continue to improve. Bocom International pointed out that earnings previews from various companies are being released this week, recommending continued focus on companies with financial performances surpassing expectations and clear paths to profitability, whose results delivery could catalyze sector performance.
Editor/Melody
